Dr. Hodi on Long-Term Survival Data for Nivolumab in Melanoma
April 17th 2016
F. Stephen Hodi, MD, director of the Melanoma Center at Dana-Farber Cancer Institute, discusses the results of the longest follow-up survival study of patients with advanced melanoma who were treated with single-agent nivolumab (Opdivo).